Overview
An essential resource for R&D professionals and clinicians with an interest in biologic therapies.
BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.
As a hybrid journal, BioDrugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).
BioDrugs also offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).
- Editor
-
- Kathy Fraser
- Impact factor
- 6.8 (2022)
- 5 year impact factor
- 6.4 (2022)
- Submission to first decision (median)
- 9 days
- Downloads
- 482,195 (2023)
Latest articles
Journal updates
-
-
-
Digital Features
BioDrugs is able to host a range of digital features, with a number of options available to authors.
Journal information
- Electronic ISSN
- 1179-190X
- Print ISSN
- 1173-8804
- Abstracted and indexed in
-
- BFI List
- BIOSIS
- Baidu
- CAB Abstracts
- CLOCKSS
- CNKI
- CNPIEC
- Chemical Abstracts Service (CAS)
- Current Contents/Clinical Medicine
- Dimensions
- EBSCO
- EMBASE
- Google Scholar
- Japanese Science and Technology Agency (JST)
- Medline
- Meta
- Naver
- OCLC WorldCat Discovery Service
- Pathway Studio
- Portico
- ProQuest
- Reaxys
- SCImago
- SCOPUS
- Science Citation Index Expanded (SCIE)
- TD Net Discovery Service
- UGC-CARE List (India)
- Wanfang
- Copyright information